论文部分内容阅读
目的探讨新辅助化疗后肺癌组织标本CerbB-2的表达及临床意义。方法采用免疫组织化学法分别检测CerbB-2在65例新辅助化疗组及39例未化疗组的宣威女性肺癌组织中的表达状况,并分析CerbB-2的表达与新辅助化疗的关系。结果肺癌新辅助化疗组CerbB-2表达率低于未化疗组(P<0.05);新辅助化疗组中有效组与无效组表达率差异有统计学意义(P<0.05)。结论CerbB-2可作为肺癌治疗的一个靶点。
Objective To investigate the expression of CerbB-2 in lung cancer tissue after neoadjuvant chemotherapy and its clinical significance. Methods The expression of CerbB-2 in 65 cases of neoadjuvant chemotherapy group and 39 cases of non-chemotherapy group were detected by immunohistochemistry. The relationship between CerbB-2 expression and neoadjuvant chemotherapy was analyzed. Results The expression of CerbB-2 in neoadjuvant chemotherapy group was lower than that in non-chemotherapy group (P <0.05). There was significant difference in the expression rate of CerbB-2 between effective group and ineffective group in neoadjuvant chemotherapy group (P <0.05). Conclusion CerbB-2 can be used as a target for the treatment of lung cancer.